- BioHarvest Sciences (BHSC) has announced that David Tsur will serve as a non-executive director of the company, effective immediately
- His appointment reinforces the company’s primary focus on becoming a biotech leader
- Mr. Tsur is the co-founder of Kamada Ltd, a bio-pharmaceutical company with a product line of specialty plasma-derived pharmaceuticals
- The board has granted Mr. Tsur 400,000 stock options
- BioHarvest Sciences is the developer and owner of a proprietary and patent-protected bio-farming technology
- BioHarvest Sciences Inc. (BHSC) is up 2.90 per cent, trading at $0.355 per share
BioHarvest Sciences (BHSC) has announced that, effective immediately, David Tsur will serve as a non-executive director of the company.
David Tsur’s 40 years of biotech experience further strengthens the board at a critical phase of the company’s growth.
His appointment reinforces the company’s primary focus on becoming a biotech leader, leveraging the power of its platform technology to disrupt multiple business verticals.
Ilan Sobel, CEO of BioHarvest, commented,
“I have spent significant time already with David and am confident he will play a key role in helping myself and the leadership team deliver on our biotech vision for the company.”
Mr. Tsur is the co-founder of Kamada Ltd, a biopharmaceutical company with a product line of specialty plasma-derived pharmaceuticals.
He also serves as chairman of Kanabo Group, a company that distributes cannabis-derived products for medical patients and non-THC products for CBD consumers.
During his career, Mr. Tsur has been responsible for generating sales of more than US$1 billion for companies operating in more than 20 countries.
“I truly believe,” said Mr. Tsur, “that BioHarvest’s proprietary BioFarming technology will revolutionise a number of industries, and I look forward to working with the board and management to fully operationalise this vision.”
The board has granted Mr. Tsur 400,000 options, exercisable to purchase a common share of the company at C$0.345 per share. The options will vest quarterly over a 3-year period and are valid for 10 years.
BioHarvest Sciences is the developer and owner of proprietary and patent-protected bio-farming technology.
The technology is capable of growing the active and beneficial ingredients in fruit and plants, at an industrial scale, without the need to grow the plant itself.
BioHarvest Sciences Inc. (BHSC) is up 2.90 per cent, trading at $0.355 per share as of 10:44 am ET.
